BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BB-1701 overview

BB-1701 is under development for the treatment of HER2 positive solid tumors including breast cancer, colon cancer, bladder cancer, gastric cancer, metastatic urothelial carcinoma, non-small cell lung cancer and gastroesophageal junction cancer. It acts by targeting HER2 and is administered by intravenous route.

Bliss Biopharmaceutical (Hangzhou) overview

Bliss Biopharmaceutical (Hangzhou), a biopharmaceutical company engaged in discovery, development and commercialization of anti-tumor macromolecular biotherapeutics. The company is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of BB-1701’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.